Get a glimpse into our company and investor data—powered by the PitchBook Platform
M&ALATEST DEAL TYPE
$489MLATEST DEAL AMOUNT
Developer of human, bi-specific antibodies used in drugs. The company specializes in the discovery and development of bi-specific and monoclonal antibodies used in pharmaceutical and therapeutic drugs.